Russell Investments Group
PYXS icon

Russell Investments Group’s Pyxis Oncology PYXS Stock Holding History

Russell Investments Group’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-64
Closed -$70 – 4210
2025
Q2 		$70 Hold
64
– – ﹤0.01% 3812
2025
Q1 		$63 Hold
64
– – ﹤0.01% 3761
2024
Q4 		$100 Hold
64
– – ﹤0.01% 3675
2024
Q3 		$235 Buy
+64
New +$224 ﹤0.01% 3624

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Russell Investments Group's PYXS Position: Q3 2025 in Review

Russell Investments Group sold out of Pyxis Oncology (PYXS) in Q3 2025, closing a stake of 64 shares — an estimated $70 sold.

Russell Investments Group first reported a position in PYXS in Q3 2024 and held it in 4 quarters. The position peaked at $235 in Q3 2024. 73 funds tracked by Wall St. Rank hold PYXS as of Q3 2025.

  • Russell Investments Group reported no remaining Pyxis Oncology position as of Q3 2025 after selling out during the quarter.
  • Russell Investments Group sold 64 Pyxis Oncology shares in Q3 2025, an estimated $70.
  • Russell Investments Group first reported a position in Pyxis Oncology in Q3 2024 and held it in 4 quarters.
  • Russell Investments Group's Pyxis Oncology position peaked at $235 in Q3 2024.
  • 73 funds tracked by Wall St. Rank held Pyxis Oncology as of Q3 2025.

Based on Russell Investments Group's 13F filing for Q3 2025, filed 13 Nov 2025.